StreetInsider.com News Articles

Form 8-K Azitra, Inc. For: Jul 15

Wed, 15 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260715/26774231.html

Form 8-K Azitra, Inc. For: Jul 15

Wed, 15 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260715/26774231.html

Azitra reports ex vivo skin elasticity and penetration data for cosmetic program

Wed, 15 Jul 2026 10:11:22 -0400

Azitra, Inc. (NYSE American: AZTR) announced results from two ex vivo human skin tissue studies evaluating its ATR-COSF program, which uses a supernatant derived from engineered S. epidermidis bacteria that secrete a recombinant human domain of the protein filaggrin (rHDfilaggrin), according to a company press release.

In the first study, a 2% lyophilized supernatant in a hydrogel formulation was applied to human skin explants that had been treated with TH2 cytokines to reduce endogenous filaggrin levels. Multiple applications produced greater penetration of rHDfilaggrin into the stratum granulosum compared to a single dose. Safety testing conducted under standardized guidelines found the formulation

Azitra reports ex vivo skin elasticity and penetration data for cosmetic program

Wed, 15 Jul 2026 10:11:22 -0400

Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity

Wed, 15 Jul 2026 10:10:00 -0400

ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value cosmetic ingredient
Ex vivo data successfully showed controlled distribution of the rHDfilaggrin into the stratum granulosum in increased amounts over prior single dose experiments in human skin
Single dose ex vivo experiments established improvements in elasticity and reduced the appearance of new fine lines and wrinkles in human skin

BRANFORD, Conn., July 15, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage

Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity

Wed, 15 Jul 2026 10:10:00 -0400

ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value cosmetic ingredient
Ex vivo data successfully showed controlled distribution of the rHDfilaggrin into the stratum granulosum in increased amounts over prior single dose experiments in human skin
Single dose ex vivo experiments established improvements in elasticity and reduced the appearance of new fine lines and wrinkles in human skin

BRANFORD, Conn., July 15, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage

Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity

Wed, 15 Jul 2026 10:10:00 -0400

ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value cosmetic ingredient
Ex vivo data successfully showed controlled distribution of the rHDfilaggrin into the stratum granulosum in increased amounts over prior single dose experiments in human skin
Single dose ex vivo experiments established improvements in elasticity and reduced the appearance of new fine lines and wrinkles in human skin

BRANFORD, Conn., July 15, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage

Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity

Wed, 15 Jul 2026 10:10:00 -0400

ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value cosmetic ingredient
Ex vivo data successfully showed controlled distribution of the rHDfilaggrin into the stratum granulosum in increased amounts over prior single dose experiments in human skin
Single dose ex vivo experiments established improvements in elasticity and reduced the appearance of new fine lines and wrinkles in human skin

BRANFORD, Conn., July 15, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage

Form SCHEDULE 13G Azitra, Inc. Filed by: Dauntless Investment Group, LLC

Thu, 25 Jun 2026 14:56:00 -0400

si-local-file:///var/storage/secattach/20260625/26691637.html

Form SCHEDULE 13G Azitra, Inc. Filed by: Dauntless Investment Group, LLC

Thu, 25 Jun 2026 14:56:00 -0400

si-local-file:///var/storage/secattach/20260625/26691637.html

Form SCHEDULE 13D Azitra, Inc. Filed by: Salva Francisco D.

Wed, 24 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260624/26682672.html

Form SCHEDULE 13D Azitra, Inc. Filed by: Salva Francisco D.

Wed, 24 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260624/26682672.html

Form SCHEDULE 13G Azitra, Inc. Filed by: Stonepine Capital Management, LLC

Mon, 22 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260622/26673965.html

Form SCHEDULE 13G Azitra, Inc. Filed by: Stonepine Capital Management, LLC

Mon, 22 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260622/26673965.html

Form 4 Azitra, Inc. For: Jun 16 Filed by: Salva Francisco D.

Thu, 18 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260618/26666597.html

Form 4 Azitra, Inc. For: Jun 16 Filed by: Salva Francisco D.

Thu, 18 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260618/26666597.html

Form 8-K Azitra, Inc. For: Jun 17

Wed, 17 Jun 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260617/26657189.html

Form 8-K Azitra, Inc. For: Jun 17

Wed, 17 Jun 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260617/26657189.html

Azitra expands into cosmetics and biotech after $10.5M financing

Wed, 17 Jun 2026 08:03:23 -0400

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on precision dermatology, outlined a strategic expansion into cosmetic ingredients and biotechnology products in a shareholder letter issued by Chief Executive Officer Francisco Salva.

The company said a March 2026 financing that raised $10.5 million, with up to an additional $21 million available through warrant exercises, is funding the new initiatives.

One new program, ATR-COSF, is a recombinant filaggrin protein candidate targeting the cosmetic skincare market, specifically aimed at reducing the appearance of fine lines and wrinkles. The company said it is conducting product optimization and ex vivo human skin studies and

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond